Halozyme Therapeutics Inc (NASDAQ: HALO) has a price-to-earnings ratio that is above its average at 14.10x. The stock has a 36-month beta value of 1.18. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 2 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for HALO is 121.86M, and at present, short sellers hold a 8.66% of that float. On June 20, 2025, the average trading volume of HALO was 2.20M shares.
HALO) stock’s latest price update
Halozyme Therapeutics Inc (NASDAQ: HALO) has experienced a rise in its stock price by 0.08 compared to its previous closing price of 53.11. However, the company has seen a fall of -1.30% in its stock price over the last five trading days. zacks.com reported 2025-06-16 that Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
HALO’s Market Performance
Halozyme Therapeutics Inc (HALO) has experienced a -1.30% fall in stock performance for the past week, with a -0.27% drop in the past month, and a -17.34% drop in the past quarter. The volatility ratio for the week is 0.75%, and the volatility levels for the past 30 days are at 1.40% for HALO. The simple moving average for the last 20 days is -1.86% for HALO’s stock, with a simple moving average of -4.94% for the last 200 days.
Analysts’ Opinion of HALO
Many brokerage firms have already submitted their reports for HALO stocks, with Morgan Stanley repeating the rating for HALO by listing it as a “Equal-Weight.” The predicted price for HALO in the upcoming period, according to Morgan Stanley is $62 based on the research report published on May 14, 2025 of the current year 2025.
Leerink Partners, on the other hand, stated in their research note that they expect to see HALO reach a price target of $47. The rating they have provided for HALO stocks is “Underperform” according to the report published on May 13th, 2025.
Wells Fargo gave a rating of “Equal Weight” to HALO, setting the target price at $62 in the report published on October 07th of the previous year.
HALO Trading at -6.87% from the 50-Day Moving Average
After a stumble in the market that brought HALO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.62% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HALO starting from Henderson Jeffrey William, who sale 4,497 shares at the price of $60.37 back on Apr 28 ’25. After this action, Henderson Jeffrey William now owns 28,611 shares of Halozyme Therapeutics Inc, valued at $271,467 using the latest closing price.
Henderson Jeffrey William, the Director of Halozyme Therapeutics Inc, sale 503 shares at $64.05 during a trade that took place back on Apr 01 ’25, which means that Henderson Jeffrey William is holding 33,108 shares at $32,217 based on the most recent closing price.
Stock Fundamentals for HALO
Current profitability levels for the company are sitting at:
- 0.55 for the present operating margin
- 0.82 for the gross margin
The net margin for Halozyme Therapeutics Inc stands at 0.45. The total capital return value is set at 0.29. Equity return is now at value 147.06, with 24.04 for asset returns.
Based on Halozyme Therapeutics Inc (HALO), the company’s capital structure generated 0.76 points at debt to capital in total, while cash flow to debt ratio is standing at 0.33. The debt to equity ratio resting at 3.13. The interest coverage ratio of the stock is 32.99.
Currently, EBITDA for the company is 656.54 million with net debt to EBITDA at 1.9. When we switch over and look at the enterprise to sales, we see a ratio of 7.27. The receivables turnover for the company is 3.56for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.39.
Conclusion
To sum up, Halozyme Therapeutics Inc (HALO) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
